Steven Devine M MD

Steven Devine M MD
ProfessorCollege of Medicinedevine.54@osu.edu
B316 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-5655Fax: (614) 293-6690
  • Leukemia Research

Research Description

Dr. Devine studies novel therapies involving the transplantation of adult blood-forming stem cells. His clini¬cal research focuses on allogeneic (donor) blood cell transplan¬tation as a treatment for advanced acute myeloid leukemia and myelodysplastic syndrome.

Current Publications

  • Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, Perales MA, Cutler CS, Bensinger W, Litzow MR, Mohty M, Champlin RE, Leather H, Giralt S, Carpenter PAPeripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant 20 1262-1273 9/1/2014
  • Haverkos BM, McBride A, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SMAn effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.Bone Marrow Transplant 49 1052-5 8/1/2014
  • Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Kwon CH, Wang QE, Devine SM, He X, Bai XF, Hofmeister CC, Yu JGenetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells.Clin Cancer Res 20 3989-4000 8/1/2014
  • Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LAThe hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.Bone Marrow Transplant in press 7/28/2014
  • Lund TC, Cathey SS, Miller WP, Eapen M, Andreansky M, Dvorak CC, Davis JH, Dalal JD, Devine SM, Eames GM, Ferguson WS, Giller RH, He W, Kurtzberg J, Krance R, Katsanis E, Lewis VA, Sahdev I, Orchard PJOutcomes after Hematopoietic Stem Cell Transplantation for Children with I-Cell Disease.Biol Blood Marrow Transplant in press 7/10/2014
  • Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum WPhase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Leuk Lymphoma 55 1304-8 6/1/2014
  • Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci GPhase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.Leuk Lymphoma 55 1332-6 6/1/2014
  • Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KAComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.Cancer 120 1677-85 6/1/2014
  • Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SMAprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.Support Care Cancer in press 5/17/2014
  • Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu JCS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.Leukemia 28 917-27 4/1/2014
  • Jaglowski SM, Devine SMGraft-versus-host disease: why have we not made more progress?Curr Opin Hematol 21 141-7 3/1/2014
  • Zhang J, Fan Z, Hofmeister CC, He X, Marsh HC, Devine SM, Yu J, He S, Chu J, Vasu S, Deng Y, Yuan SFLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.Biol Blood Marrow Transplant 20 309-13 3/1/2014
  • McCarty J, Shaughnessy P, Snyder E, Bensinger W, Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine SOptimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.Biol Blood Marrow Transplant 20 295-308 3/1/2014
  • Devine SMReprint of: Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.Biol Blood Marrow Transplant 20 S2-S7 2/1/2014
  • Devine SMRe-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.Biol Blood Marrow Transplant 20 14-9 1/1/2014
  • Armstrong E, Smith A, Rizzo JD, Burkart JM, Pasquini MC, Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KRProspective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Blood 122 3871-8 12/5/2013
  • Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LIDisabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.J Clin Oncol 31 4199-206 11/20/2013
  • Lustberg M, Devine S, Elder P, Andritsos L, Martin SI, Abandeh FIOutcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study.Bone Marrow Transplant 48 1554-7 11/1/2013
  • O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H, Ntational comprehensive cancer network, Jagasia MChronic Myelogenous Leukemia, Version 1.2014.J Natl Compr Canc Netw 11 1327-40 11/1/2013
  • Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti DPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.J Clin Invest 123 4144-57 10/1/2013
  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48 1212-7 9/1/2013
  • Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy NGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs 5 723-35 9/1/2013
  • Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA, Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BSStandard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Clin Pharmacokinet 52 705-12 8/1/2013
  • Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YAEarly versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Leuk Lymphoma 54 1658-64 8/1/2013
  • He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM Jr, Hofmeister CC, He X, Ghoshal K, Devine SM, Caligiuri MA, Yu JMicroRNAs activate natural killer cells through Toll-like receptor signaling.Blood 121 4663-71 6/6/2013
  • Shaughnessy P, Uberti J, Devine S, Maziarz RT, Vose J, Micallef I, Jacobsen E, McCarty J, Stiff P, Artz A, Ball ED, Berryman R, Dugan M, Joyce R, Hsu FJ, Johns D, McSweeney PPlerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.Bone Marrow Transplant 48 777-81 6/1/2013
  • Champlin RE, Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen MWho is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?Blood 121 2567-73 3/28/2013
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar RMultiple myeloma, version 1.2013.J Natl Compr Canc Netw 11 11-7 1/1/2013
  • Devine SMToward a more rational policy for autologous hematopoietic stem cell mobilization.Biol Blood Marrow Transplant 18 1468-70 10/1/2012
  • Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA, NCCN (National Comprehensive Cancer Network), Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto CWaldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.J Natl Compr Canc Netw 10 1211-9 10/1/2012
  • Bruce JT, Tran JM, Phillips G, Elder P, Mastronarde JG, Devine SM, Hofmeister CC, Wood KLChemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.Clin Lymphoma Myeloma Leuk 12 325-9 10/1/2012
  • Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LAComplex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.Br J Haematol 159 82-7 10/1/2012
  • Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, O'Reilly RJ, Soiffer RJ, Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JRComparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.J Clin Oncol 30 3194-201 9/10/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu